查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607044

局部性肾小球硬化症市场：按药物类别、阶段、分销管道、最终用户划分 - 全球预测 2025-2030

Focal Segmental Glomerulosclerosis Market by Drug Class (Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Corticosteroids), Stage (Primary, Secondary), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

局部节段性肾丝球硬化市场2023年估值为161.9亿美元，预计2024年将达到174.1亿美元，复合年增长率为7.83%，2030年将达27.4亿美元，预计将达到5000万亿美元。

局部节段性肾丝球硬化症 (FSGS) 是一种罕见的肾臟疾病，其特征是部分肾小球出现疤痕，导致肾功能严重受损。市场的范围和定义围绕着製药和医疗保健领域，其中免疫抑制剂、ACE抑制剂和新生物製药等先进的治疗方法至关重要。这些治疗旨在减缓疾病的进展并改善患者的生活品质。这些治疗方法的应用范围广泛，包括医院、诊所和肾臟科中心。最终用途范围包括优先考虑创新治疗策略的医疗保健提供者、製药公司和研究机构。关键的成长要素包括慢性肾臟病盛行率的上升、认识的提高以及诊断技术的进步。 FSGS 的日益普及正在推动研究和开发，为药物发现、个人化医疗和微创治疗提供了充满希望的机会。用于早期检测的生物标记研究和用于开发标靶治疗的基因研究等领域提供了巨大的商机。然而，高昂的治疗费用和有限的治疗效果等限制已成为主要挑战。罕见疾病的本质阻碍了市场成长，它使临床试验过程变得复杂并阻碍了投资。此外，监管障碍和缺乏全面的患者登记也为市场扩张带来了挑战。业务成长的创新领域包括基因疗法的开发和扩大我们对 FSGS病理学的理解。生物技术公司和学术机构之间的合作也可能催生新的治疗解决方案。儘管市场动态复杂，但投资以患者为中心的护理模式并利用数位健康技术可以改善患者的治疗结果和市场潜力。因此，这个市场的本质是利基市场，但仍在不断发展，要求相关人员继续适应技术进步和监管环境，同时有效满足患者需求。

主要市场统计
基准年[2023] 161.9亿美元
预计年份 [2024] 174.1亿美元
预测年份 [2030] 274.5亿美元
复合年增长率（%） 7.83%

市场动态：快速发展的局部节段性肾小球硬化症市场的关键市场洞察

供需的动态交互作用正在改变局部节段性肾丝球硬化症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于遗传和非遗传因素导致 FSGS 病例增加
    • 人们对肾臟疾病和 FSGS 治疗的认识不断提高
    • 透过线上药局增加 FSGS 治疗的可用性
  • 市场限制因素
    • 治疗费用上涨且报销有限
  • 市场机会
    • 持续研究并开发推出 FSGS 疗法的新剂型
    • 政府对 FSGS 治疗和药物的有利核准
  • 市场挑战
    • 对 FSGS 治疗的免疫抑制和副作用的担忧

波特的五力：驾驭局部节段性肾丝球硬化症市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解局部节段性肾丝球硬化症市场的外部影响

外部宏观环境因素在塑造局部节段性肾丝球硬化症市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解局部节段性肾丝球硬化症市场的竞争格局

对局部节段性肾丝球硬化症市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵局部节段性肾丝球硬化症市场供应商的绩效评估

FPNV定位矩阵是评估局部节段性肾丝球硬化症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了局部节段性肾小球硬化症市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对局部节段性肾小球硬化症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于遗传和非遗传因素导致 FSGS 病例增加
      • 人们对肾臟疾病和 FSGS 治疗的认识不断提高
      • 透过线上药局可得性
    • 抑制因素
      • 治疗费用高，治疗报销有限。
    • 机会
      • 持续研发推出针对 FSGS 的新药物治疗方案
      • 政府对 FSGS 药物和疗法的有利核准
    • 任务
      • 对 FSGS 治疗的免疫抑制和副作用的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章依药物类别分類的局部节段性肾丝球硬化症市场

  • 血管收缩素受体阻断剂
  • 血管张力素转化酵素抑制剂
  • 皮质类固醇
  • 利尿剂

第七章局部节段性肾丝球硬化症市场：依阶段

  • 基本的
  • 中学

第八章局部节段性肾丝球硬化症市场：依分销管道

  • 离线
  • 在线的

第 9 章 局部节段性肾丝球硬化症市场：依最终用户分类

  • 门诊手术中心
  • 家庭护理设置
  • 医院/诊所

第10章美洲局部节段肾丝球硬化市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太区域性节段性肾丝球硬化市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲局部节段性肾丝球硬化市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • CMG Biotech Pvt. Ltd.
  • Dr Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • FDC Ltd.
  • Fresenius Kabi
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Medley Pharmaceuticals Ltd.
  • Micro Labs Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Sunij Pharma Pvt Ltd.
  • Teva Pharmaceutical industries Ltd.
  • USV Ltd.
  • Viatris
  • ZEE Laboratories Limited
  • Zydus Healthcare Limited
Product Code: MRR-C002B1C994EF

The Focal Segmental Glomerulosclerosis Market was valued at USD 16.19 billion in 2023, expected to reach USD 17.41 billion in 2024, and is projected to grow at a CAGR of 7.83%, to USD 27.45 billion by 2030.

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring in parts of the glomeruli, leading to significant impairment in kidney function. The market scope and definition revolve around the pharmaceutical and healthcare sectors, where there's a critical necessity for advanced therapeutic approaches such as immunosuppressants, ACE inhibitors, and emerging biologics. These treatments aim to slow disease progression and improve quality of life for patients. The application of these treatments spans across hospitals, clinics, and specialty nephrology centers. The end-use scope involves healthcare providers, pharmaceutical companies, and research institutions prioritizing innovative treatment strategies. Key growth influencers include rising incidence rates of chronic kidney diseases, increased awareness, and advancements in diagnostic technologies. The growing prevalence of FSGS drives research and development, leading to promising opportunities in drug discovery, personalized medicine, and minimally invasive therapies. Areas like biomarker research for early detection and genetic studies for developing targeted therapies offer significant business opportunities. However, limitations such as high treatment costs and limited therapeutic efficacy pose significant challenges. The market growth is hampered by the rare nature of the disease, which complicates clinical trial processes and reduces investment incentives. Additionally, regulatory hurdles and lack of comprehensive patient registries challenge market expansion. Innovative areas for business growth include developing gene therapies and expanding the understanding of FSGS pathophysiology. Collaborations between biotech firms and academic institutions can also foster novel treatment solutions. Despite the complex market dynamics, investing in patient-centric care models and leveraging digital health technologies can enhance patient outcomes and market potential. Consequently, the nature of this market remains niche yet evolving, requiring stakeholders to stay adaptive to technological advancements and regulatory landscapes while addressing patient needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 16.19 billion
Estimated Year [2024] USD 17.41 billion
Forecast Year [2030] USD 27.45 billion
CAGR (%) 7.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Focal Segmental Glomerulosclerosis Market

The Focal Segmental Glomerulosclerosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of FSGS due to genetic and non-genetic factors
    • Rising awareness about kidney disease and FSGS treatment
    • Increasing availability of FSGS medications through online pharmacies
  • Market Restraints
    • High cost and limited reimbursement available for treatment
  • Market Opportunities
    • Ongoing R&D in introducing new drug formulations for FSGS
    • Favorable government approvals for FSGS drugs and medications
  • Market Challenges
    • Concerns associated with immunosuppression and side effects of FSGS drugs

Porter's Five Forces: A Strategic Tool for Navigating the Focal Segmental Glomerulosclerosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Focal Segmental Glomerulosclerosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Focal Segmental Glomerulosclerosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Focal Segmental Glomerulosclerosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Focal Segmental Glomerulosclerosis Market

A detailed market share analysis in the Focal Segmental Glomerulosclerosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Focal Segmental Glomerulosclerosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Focal Segmental Glomerulosclerosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Focal Segmental Glomerulosclerosis Market

A strategic analysis of the Focal Segmental Glomerulosclerosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Focal Segmental Glomerulosclerosis Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Cipla Ltd., CMG Biotech Pvt. Ltd., Dr Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, FDC Ltd., Fresenius Kabi, Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunij Pharma Pvt Ltd., Teva Pharmaceutical industries Ltd., USV Ltd., Viatris, ZEE Laboratories Limited, and Zydus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Focal Segmental Glomerulosclerosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Corticosteroids, and Diuretics.
  • Based on Stage, market is studied across Primary and Secondary.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of FSGS due to genetic and non-genetic factors
      • 5.1.1.2. Rising awareness about kidney disease and FSGS treatment
      • 5.1.1.3. Increasing availability of FSGS medications through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited reimbursement available for treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D in introducing new drug formulations for FSGS
      • 5.1.3.2. Favorable government approvals for FSGS drugs and medications
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with immunosuppression and side effects of FSGS drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Focal Segmental Glomerulosclerosis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Angiotensin Receptor Blockers
  • 6.3. Angiotensin-Converting Enzyme Inhibitors
  • 6.4. Corticosteroids
  • 6.5. Diuretics

7. Focal Segmental Glomerulosclerosis Market, by Stage

  • 7.1. Introduction
  • 7.2. Primary
  • 7.3. Secondary

8. Focal Segmental Glomerulosclerosis Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Focal Segmental Glomerulosclerosis Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Homecare Settings
  • 9.4. Hospitals & Clinics

10. Americas Focal Segmental Glomerulosclerosis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Focal Segmental Glomerulosclerosis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Focal Segmental Glomerulosclerosis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Cipla Ltd.
  • 3. CMG Biotech Pvt. Ltd.
  • 4. Dr Reddy's Laboratories Ltd.
  • 5. F. Hoffmann-La Roche AG
  • 6. FDC Ltd.
  • 7. Fresenius Kabi
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. GSK PLC
  • 10. Hikma Pharmaceuticals PLC
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Lupin Ltd.
  • 13. Mankind Pharma Ltd.
  • 14. Medley Pharmaceuticals Ltd.
  • 15. Micro Labs Ltd.
  • 16. Novartis AG
  • 17. Pfizer, Inc.
  • 18. Sanofi S.A.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Sunij Pharma Pvt Ltd.
  • 21. Teva Pharmaceutical industries Ltd.
  • 22. USV Ltd.
  • 23. Viatris
  • 24. ZEE Laboratories Limited
  • 25. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023